文献速递心力衰竭与心肌病

达格列净用于心力衰竭住院患者:DAPA ACT HF-TIMI 68 随机临床试验主要结果及 SGLT2 抑制剂荟萃分析

Dapagliflozin in Patients Hospitalized for Heart Failure: Primary Results of the DAPA ACT HF-TIMI 68 Randomized Clinical Trial and Meta-Analysis of Sodium-Glucose Cotransporter-2 Inhibitors in Patients Hospitalized for Heart Failure.
PubMed 文献 · Circulation · 2025-08-29

在 2401 例心衰住院患者中,住院期间启动达格列净 10 mg/d 与安慰剂相比,2 个月内心血管死亡或心衰恶化的复合终点无显著降低(HR 0.86,95%CI 0.68-1.08,P=0.20)。预设荟萃分析显示,SGLT2 抑制剂可降低心衰住院患者早期心血管死亡或心衰恶化风险(HR 0.71,95%CI 0.54-0.93,P=0.012)及全因死亡风险(HR 0.57,95%CI 0.41-0.80,P=0.001)。

要点

  • 住院期间启动达格列净未显著降低2个月心血管死亡或心衰恶化复合终点。
  • 预设荟萃分析支持住院期间启动SGLT2抑制剂可降低早期心血管死亡或心衰恶化及全因死亡风险。
  • 达格列净组症状性低血压3.6% vs 2.2%,肾功能恶化5.9% vs 4.7%。

核心结论

  • 在本试验中,心衰住院患者住院期间启动达格列净未显著降低2个月内心血管死亡或心衰恶化风险。
  • 然而,随机临床试验总体数据提示住院期间启动SGLT2抑制剂可能降低早期心血管死亡或心衰恶化及全因死亡风险。

研究设计与样本

  • 随机、双盲、安慰剂对照试验,评估心衰住院患者住院期间启动达格列净10 mg/d的疗效与安全性。
  • 共随机2401例患者,达格列净组1218例,安慰剂组1183例;中位年龄69岁,女性815例(33.9%),黑人448例(18.7%),LVEF≤40%者1717例(71.5%)。
  • 预设对评估心衰住院患者启动SGLT2抑制剂的随机试验进行荟萃分析。

主要发现

  • 主要复合终点(心血管死亡或心衰恶化)达格列净组133例(10.9%),安慰剂组150例(12.7%)(HR 0.86,95%CI 0.68-1.08,P=0.20)。
  • 心衰恶化事件达格列净组115例(9.4%),安慰剂组122例(10.3%)(HR 0.91,95%CI 0.71-1.18)。
  • 心血管死亡达格列净组30例(2.5%),安慰剂组37例(3.1%)(HR 0.78,95%CI 0.48-1.27)。
  • 全因死亡达格列净组36例(3.0%),安慰剂组53例(4.5%)(HR 0.66,95%CI 0.43-1.00)。
  • 荟萃分析显示SGLT2抑制剂降低早期心血管死亡或心衰恶化风险(HR 0.71,95%CI 0.54-0.93,P=0.012)及全因死亡风险(HR 0.57,95%CI 0.41-0.80,P=0.001)。

关键数值与推荐

  • 主要疗效终点为至2个月心血管死亡或心衰恶化的复合终点时间。
  • 关键安全性终点包括症状性低血压和肾功能恶化;达格列净组症状性低血压发生率3.6%,安慰剂组2.2%。
  • 达格列净组肾功能恶化发生率5.9%,安慰剂组4.7%。

临床怎么用

  • 住院期间启动达格列净在本试验中未显著改善2个月主要复合终点,但安全性事件需关注症状性低血压和肾功能恶化。
  • 结合荟萃分析结果,住院期间启动SGLT2抑制剂可能为心衰住院患者带来早期获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: SGLT2 (sodium-glucose cotransporter-2) inhibitors reduce the risk of cardiovascular death or worsening heart failure (HF) in outpatients with HF. Data on initiation in patients hospitalized for HF are limited. METHODS: We conducted a randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of in-hospital initiation of dapagliflozin (10 mg daily) in patients hospitalized for HF. The primary efficacy outcome was a composite of time to cardiovascular death or worsening HF through 2 months. Key safety outcomes included symptomatic hypotension and worsening kidney function. A prespecified meta-analysis of randomized trials evaluating initiation of SGLT2 inhibitors in patients hospitalized for HF was performed. RESULTS: Of 2401 patients (median age, 69 [Q1-Q3, 58-77] years, 815 [33.9%] women, 448 [18.7%] Black race, 1717 [71.5%] left ventricular ejection fraction ≤40%, 1074 [44.7%] newly diagnosed HF) randomized between September 2020 and March 2025, 1218 were assigned to dapagliflozin and 1183 to placebo. The primary outcome occurred in 133 patients (10.9%) in the dapagliflozin group and 150 (12.7%) in the placebo group (hazard ratio [HR], 0.86 [95% CI, 0.68-1.08]; P=0.20). A worsening HF event occurred in 115 (9.4%) and 122 (10.3%) patients in the dapagliflozin and placebo groups, respectively (HR, 0.91 [95% CI, 0.71-1.18]). Cardiovascular death occurred in 30 (2.5%) and 37 (3.1%) patients (HR, 0.78 [95% CI, 0.48-1.27]), and death from any cause occurred in 36 (3.0%) and 53 (4.5%) patients in the dapagliflozin and placebo groups, respectively (HR, 0.66 [95% CI, 0.43-1.00]). The rates of symptomatic hypotension were 3.6% and 2.2%, and the rates of worsening kidney function were 5.9% and 4.7% with dapagliflozin and placebo, respectively. In a meta-analysis of patients hospitalized for HF, SGLT2 inhibitors reduced the early risk of cardiovascular death or worsening HF (HR, 0.71 [95% CI, 0.54-0.93] P=0.012) and of all-cause death (HR, 0.57 [95% CI, 0.41-0.80]; P=0.001). CONCLUSIONS: In this trial, in-hospital initiation of dapagliflozin did not significantly reduce the risk of cardiovascular death or worsening HF through 2 months in hospitalized HF patients. However, the totality of randomized clinical trial data suggests that in-hospital initiation of SGLT2 inhibitors may reduce the early risk of cardiovascular death or worsening HF and of all-cause mortality. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT04363697.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Berg, Patel, Haller, et al. Dapagliflozin in Patients Hospitalized for Heart Failure: Primary Results of the DAPA ACT HF-TIMI 68 Randomized Clinical Trial and Meta-Analysis of Sodium-Glucose Cotransporter-2 Inhibitors in Patients Hospitalized for Heart Failure. Circulation. 2025. PMID: 40884036. doi:10.1161/CIRCULATIONAHA.125.076575

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。